Enlivex Therapeutics Ltd (ENLV) Live Share Price, Invest From India

Enlivex Therapeutics Ltd Stock Performance

as on January 28, 2026 at 9:33 pm IST

Day's Low
Day's High
$1.14
Day's Price Range
$1.18
$1.16
1.72%
Downside
1.72%
Upside
52 Week's Low
52 Week's High
$0.66
52-Week Price Range
$2.10
$1.16
43.10%
Downside
81.03%
Upside

Enlivex Therapeutics Ltd share price movements today

Previous Close: $1.20
Open: $1.17
Volume: 407.0K
Day's Low - High: $1.14 - $1.18
52 Week Low - High: $0.66 - $2.10

Enlivex Therapeutics Ltd Historical Returns

1 Month Return: + 60.49 %
3 Month Return: + 11.11 %
1 Year Return: + 6.19 %
3 Year Return: -72.85 %
5 Year Return: -89.87 %

Enlivex Therapeutics Ltd Stock Fundamentals & Key Indicators

Check Enlivex Therapeutics Ltd market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$277.7M

EPS (TTM)

-0.395

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-14.3M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-57.64%

Enlivex Therapeutics Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Enlivex Therapeutics Ltd with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Enlivex Therapeutics Ltd	BUY	$277.7M	-89.87%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$47.7B	129.26%	1246.03	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$122.3B	106.13%	33.56	31.35%
Beone Medicines Ltd	NA	$37.4B	NA	662.33	1.38%
Regeneron Pharmaceuticals, Inc.	BUY	$80.8B	52.34%	18.28	32.13%

Stock Returns calculator for Enlivex Therapeutics Ltd Stock including INR - Dollar returns

The Enlivex Therapeutics Ltd stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Enlivex Therapeutics Ltd investment value today

Current value as on today

₹1,08,629

Returns

₹8,629

(+8.63%)

Returns from Enlivex Therapeutics Ltd Stock

₹2,655 (+2.65%)

Dollar Returns*

₹5,974 (+5.97%)

Analyst Recommendation on Enlivex Therapeutics Ltd Stock

Based on 7 analysts

BUY

85.71%

Buy

14.29%

Hold

0.00%

Sell

Based on 7 analysts, 85.71% of analysts recommend a 'BUY' rating for Enlivex Therapeutics Ltd. Average target price of $13

Enlivex Therapeutics Ltd Share Price Target

Get share price movements and forecasts by analysts on Enlivex Therapeutics Ltd.

What analysts predicted

91.08%UPSIDE

Target Price

$13

Current Price

$1.16

Analyzed by

7 Analysts

Target

$13.00

Enlivex Therapeutics Ltd target price $13, a slight upside of 91.08% compared to current price of $1.16. According to 7 analysts rating.

Enlivex Therapeutics Ltd Stock’s Investor Sentiment and Interest

Search interest for Enlivex Therapeutics Ltd Stock has decreased by -21% in the last 30 days, reflecting a downward trend in search activity.

Time period: December 29, 2025 to January 28, 2026

Change:-21% versus previous 30 day period

Enlivex Therapeutics Ltd Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	-	0	0	0
Operating Income	-6	-5	-6	-3	-2	-3	-4	-3	-3	-2
EBITDA	-6	-5	-5	-3	-2	-2	-	-3	-2	-2
Interest Expense	-	-	-	-	0	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-6	-5	-9	-4	-3	-2	-5	-3	-1	-2
Income Tax Expense	0	0	0	0	-	-	-	-	-	-
Net Income	-6	-5	-9	-4	-3	-2	-5	-3	-1	-2
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Enlivex Therapeutics Ltd Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	-	-	-	-	2	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0
Operating Income	-15	-5	-5	-8	-9	-19	-25	-29	-15
EBITDA	-15	-5	-5	-9	-9	-18	-25	-28	-14
Interest Expense	-	-	-	0	0	0	5	0	0
Depreciation	-	0	0	0	0	0	0	0	0
Income Before Tax	-15	-5	-4	-9	-11	-14	-31	-29	-15
Income Tax Expense	0	0	1	0	2	-4	11	4	-
Net Income	-16	-5	-4	-9	-11	-14	-31	-29	-15
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-519.28%	0.00%	0.00%	0.00%	0.00%

Enlivex Therapeutics Ltd Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-5	-9	-4	-3	-2	-5	-3	-1	-2
Operating Cash Flow	-5	-5	-4	-1	-2	-4	-4	-1	-2
Investing Cash Flow	3	4	5	0	1	-	3	1	4
Financing Cash Flow	0	0	0	4	0	1	0	0	0
Change in Cash	-1	-1	1	1	0	0	-1	0	2

Enlivex Therapeutics Ltd Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-16	-5	-4	-9	-11	-14	-31	-29	-15
Operating Cash Flow	-15	-6	-3	-7	-11	-17	-23	-23	-13
Investing Cash Flow	8	3	0	-6	-20	-38	62	-25	9
Financing Cash Flow	6	0	5	8	33	60	0	0	6
Change in Cash	0	-3	0	-4	1	4	38	-49	2

Global Institutional Holdings in Enlivex Therapeutics Ltd

Funds	Holdings
Armistice Capital, LLC	5.93%
JPMorgan Chase & Co	0.01%
SignatureFD, LLC	0.02%
Steward Partners Investment Advisory, LLC	0.01%
Activest Wealth Management	0%

See all

Insights on Enlivex Therapeutics Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, ENLV stock has moved up by 22.3%
NO EFFECT
Against Peers
In the last 1 year, Beone Medicines Ltd has given 48.3% return, outperforming this stock by 42.1%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 29.4% return, outperforming this stock by 102.3%

About Enlivex Therapeutics Ltd

enlivex therapeutics ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. its product candidate is allocetra, an immunotherapy candidate, which is in phase iib clinical trial in patients with severe sepsis; that is in investigator-initiated phase ii clinical trial for the treatment of covid-19 patients in severe and critical conditions; and which is in phase iia clinical trial for the prevention of graft versus host disease in allogeneic hematopoietic stem cell transplants (hsct) patients. the company is also developing allocetra for the prevention of complications associated with bone marrow transplantations and/or hsct, and acute multiple organ failure. it also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor t-cell therapy and therapies targeting t-cell re

Organisation	Enlivex Therapeutics Ltd
Headquarters	14 Einstein Street, Ness Ziona, Israel, 7403618
Industry	Biotechnology
CEO	Dr. Oren Hershkovitz Ph.D.
E-voting on shares	Click here to vote

Key Management of Enlivex Therapeutics Ltd

Name	Title
Dr. Einat Galamidi M.D.	Chief Medical Officer
Mr. Shai Novik M.B.A.	Executive Chairman
Dr. Oren Hershkovitz Ph.D.	Chief Executive Officer
Prof. Dror Mevorach M.D.	Founder & Scientific Advisor
Ms. Shachar Shlosberger CPA	Chief Financial Officer
Dr. Veronique Amor-Baroukh	Senior Director of Operations
Ms. Sigal Arad	Director of Human Resources

FAQs

What is Enlivex Therapeutics Ltd share price today?

Enlivex Therapeutics Ltd share price today is $1.16 as on January 28, 2026 at 9:33 pm IST. Enlivex Therapeutics Ltd share today touched a day high of $1.18 and a low of $1.14.

What is the 52 week high and 52 week low for Enlivex Therapeutics Ltd share?

Enlivex Therapeutics Ltd share touched a 52 week high of $2.1 on August 15, 2025 and a 52 week low of $0.66 on December 31, 2025. Enlivex Therapeutics Ltd stock price today i.e. January 28, 2026 at 9:33 pm IST is trending at $1.16,which is 44.76% down from its 52 week high and 75.76% up from its 52 week low.

What is Enlivex Therapeutics Ltd's market capitalisation today?

Enlivex Therapeutics Ltd market capitalisation is $0.00T as on January 28, 2026 at 9:33 pm IST.

How to invest in Enlivex Therapeutics Ltd Stock (ENLV) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Enlivex Therapeutics Ltd on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Enlivex Therapeutics Ltd Shares that will get you 1.2931 shares as per Enlivex Therapeutics Ltd share price of $1.16 per share as on January 28, 2026 at 9:33 pm IST.

What is the minimum amount required to buy Enlivex Therapeutics Ltd Stock (ENLV) from India?

Indian investors can start investing in Enlivex Therapeutics Ltd (ENLV) shares with as little as ₹91.762 or $1 (as of January 28, 2026 at 9:39 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹917.62 in Enlivex Therapeutics Ltd stock (as per the Rupee-Dollar exchange rate as on January 28, 2026 at 9:39 pm IST). Based on Enlivex Therapeutics Ltd share’s latest price of $1.16 as on January 28, 2026 at 9:33 pm IST, you will get 8.6207 shares of Enlivex Therapeutics Ltd. Learn more about fractional shares .

What are the returns that Enlivex Therapeutics Ltd has given to Indian investors in the last 5 years?

Enlivex Therapeutics Ltd stock has given -89.87% share price returns and 25.73% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?